Dr. Michael Hildebrand, associate professor of neuroscience at Carleton University, highlights his recent work aimed at bridging the translational divide between target identification in rodent models of chronic pain and direct clinical testing of candidate compounds in humans. His research team has developed a novel human spinal cord tissue model of pathological pain that parallels rodent in vivo and ex vivo pain models. Using these complementary approaches, Dr. Hildebrand and his team are identifying molecular determinants of spinal cord hyperexcitability that are conserved across species, and thus may inform the rational development of more effective therapeutics for chronic pain.

Dr. Cesare Terracciano, professor of cardiac electrophysiology at Imperial College London, presents “Myocardial Slices as Novel Discovery Model to Study Biology of the Human Heart.” In this 45-minute webinar, Dr. Terracciano discusses the limitations of the current cardiac models and unmet needs. He also summarizes his work to develop myocardial slice preparation methodology, and outlines its unique advantages and applications for translational cardiovascular science and drug testing.
Dr. Patrick Dougherty, professor in cancer research at The University of Texas MD Anderson Cancer Center, presents original pain research in AnaBios’ webinar, “Treatment Targets for Chemotherapy-Induced Peripheral Neuropathy: Clues from Studies on Ectopic Spontaneous Activity.” Dr. Dougherty’s research indicates that spontaneous activity in human dorsal root ganglia (DRG) neurons is linked to reports of neuropathic pain from the patients who donated their organs for the study.
In this 30-minute webinar, CEO Andre Ghetti introduces a new human translational strategy for advancing analgesic drug discovery based on utilizing primary human peripheral neurons to assess a drug candidate’s potential efficacy. This human-focused translational paradigm bypasses risks related to cross-species differences and enables the study of drug effects in the context of pathological pain states.
In this informative, 30-minute webinar, Dr. Najah Abi-Gerges, Vice President of Research & Development at AnaBios, presents human adult primary cardiomyocyte research for cardiac safety assessment. During the presentation, Dr. Abi-Gerges addresses novel approaches enabling the study of primary human cardiomyocytes,  and their use for assessing cardiac safety. Other topics include:
  • Pro-arrhythmia & contractility risk
  • Human primary atrial cells in atrial fibrillation drug discovery
  • Advancing the understanding of heart failure and new therapies with human primary ventricular myocytes and tissues